Breckenridge Pharmaceutical Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Breckenridge Pharmaceutical Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011816
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Breckenridge Pharmaceutical Inc (Breckenridge), a subsidiary of Laboratorios Del Dr Esteve SA is a healthcare solution provider that research, develops and markets various generic prescription products. The company provides products including stradiol, oxcarbazepine tablets, methylprednisolone, polyethylene glycol powder, caffeine, codeine phosphate, meloxicam tablets, butalbital, acetaminophen, cyclobenzaprine, folic acid tablets and prednisone. Breckenridge produces its products in the dosage forms of tablets, capsules, liquids, suspensions, soft gel capsules and powders. It distributes products through a network of wholesalers, distributors, chains, managed care accounts and retail pharmacies. The company has presence in Berlin, Boca Raton, Fairfield and New York. Breckenridge is headquartered in Boca Raton, Florida, the US.

Breckenridge Pharmaceutical Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Breckenridge Pharma Acquires Five ANDA’s from Nostrum Lab 11
Breckenridge Pharma Acquires ANDA from Impopharma 12
Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For US$30 Million 13
Partnerships 15
Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 15
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 16
Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 17
Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 18
Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 19
Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 20
Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 21
Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 22
Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 23
Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 24
Breckenridge Pharma Enters Into Co-Marketing Agreement With Oman Pharma Products 25
Breckenridge Pharmaceutical Inc – Key Competitors 26
Breckenridge Pharmaceutical Inc – Key Employees 27
Breckenridge Pharmaceutical Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts 2
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Breckenridge Pharmaceutical Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Breckenridge Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Breckenridge Pharma Acquires Five ANDA's from Nostrum Lab 11
Breckenridge Pharma Acquires ANDA from Impopharma 12
Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For US$30 Million 13
Breckenridge Pharma Enters into Agreement with Sam Chun Dang Pharm 15
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 16
Breckenridge Pharma Enters into Co-Marketing Agreement with MSN Labs for ANDAs 17
Breckenridge Pharma Enters into Co-Development Agreement with Pharmaceutics International 18
Breckenridge Pharma Enters Into Co-Development Agreement With Welding And SK Chemicals 19
Breckenridge Pharma Enters Into Co-Marketing Agreement With Aptalis Pharmatech For Inderal LA 20
Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 21
Breckenridge Pharma Enters Into Co-Marketing Agreement With Ajanta Pharma For Risperdal Tablet 22
Pamlab Enters Into Joint Venture With Breckenridge To Distribute Medical Food Products 23
Breckenridge Pharma Enters Into Co-Marketing Agreement With Zhejiang Huahai Pharma For Nevirapine 24
Breckenridge Pharma Enters Into Co-Marketing Agreement With Oman Pharma Products 25
Breckenridge Pharmaceutical Inc, Key Competitors 26
Breckenridge Pharmaceutical Inc, Key Employees 27
Breckenridge Pharmaceutical Inc, Other Locations 28

★海外企業調査レポート[Breckenridge Pharmaceutical Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • QuantuMDx Group Ltd:医療機器:M&Aディール及び事業提携情報
    Summary QuantuMDx Group Ltd (QuantuMDx) is a developer of sciences tools and diagnostics products. The company’s products include Q-POC, a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious dise …
  • Windflow Technology Limited (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Limited (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • CME Group Inc:企業のM&A・事業提携・投資動向
    CME Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CME Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Graphic Packaging Holding Company:戦略・SWOT・企業財務分析
    Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report Summary Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Hunan Fangsheng Pharmaceutical Co Ltd (603998):製薬・医療:M&Aディール及び事業提携情報
    Summary Hunan Fangsheng Pharmaceutical Co Ltd (Fangsheng Pharma) is a research-based comprehensive pharmaceutical enterprise offers research, development, manufacturing and sales of pharmaceuticals. The enterprise’ products include tablets, capsules, granules, oral suspension, powder, suppository, p …
  • Innate Pharma SA (IPH)-製薬・医療分野:企業M&A・提携分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • Shimadzu Corp (7701):医療機器:M&Aディール及び事業提携情報
    Summary Shimadzu Corp (Shimadzu) is a manufacturer of precision instruments, measuring instruments and medical equipment. The company’s product portfolio includes high performance liquid chromatographs (HPLC), spectrometers, carbon analyzer, X-ray systems, inspection systems, semiconductor manufactu …
  • HedgePath Pharmaceuticals Inc (HPPI):製薬・医療:M&Aディール及び事業提携情報
    Summary Hedgepath Pharmaceuticals Inc (Hedgepath), a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of skin, prostrate, and lung cancers. The company is investigating an oral formula …
  • Pernod Ricard SA:戦略・SWOT・企業財務分析
    Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report Summary Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Burmeister & Wain Scandinavian Contractor AS:企業の戦略的SWOT分析
    Burmeister & Wain Scandinavian Contractor AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Hitachi Zosen Corporation (7004):企業の財務・戦略的SWOT分析
    Hitachi Zosen Corporation (7004) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Louisiana-Pacific Corporation:戦略・SWOT・企業財務分析
    Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report Summary Louisiana-Pacific Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • EnerSys (ENS):電力:M&Aディール及び事業提携情報
    Summary EnerSys is a provider of stored energy solutions. It manufactures, markets, and distributes reserve power and motive power batteries, power equipment, battery accessories, battery chargers, and outdoor equipment enclosure solutions. The company also related aftermarket and customer-support s …
  • Marker Therapeutics Inc (MRKR):企業の財務・戦略的SWOT分析
    Summary Marker Therapeutics Inc (Marker Therapeutics) is formerly known as TapImmune Inc is a clinical-stage immuno-oncology company focus on the development of innovative peptide, gene-based immuno therapeutics and vaccines for the treatment of cancer and metastatic disease. The company’s pipeline …
  • Oci Nv:企業の戦略・SWOT・財務分析
    Oci Nv - Strategy, SWOT and Corporate Finance Report Summary Oci Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Victek Co., Ltd.:企業の戦略・SWOT・財務分析
    Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Paladin Energy Ltd (PDN)
    Paladin Energy Ltd (PDN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Volex plc (VLX):企業の財務・戦略的SWOT分析
    Volex plc (VLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Grundfos Holding AS:企業の戦略的SWOT分析
    Grundfos Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Critical Outcome Technologies Inc (COT)-製薬・医療分野:企業M&A・提携分析
    Summary Critical Outcome Technologies Inc (COTI) is a biopharmaceutical company that develops targeted therapeutics with focus on oncology. The company’s lead program COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological canc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆